Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Articles|October 6, 2022
UCSF Department of Urology Grand Rounds with Dr. Ezekiel J. Emanuel: October 14
Author(s)UCSF Health
Advertisement
Join the discussion on Health Reform with world leader in health policy and bioethics, Ezekiel J. Emanuel, MD, PhD, the Vice Provost for Global Initiatives and expert panelists and UCSF leaders.
Listen to Dr. Zeke Emanuel share his thoughts on the future of automation in medicine followed by a panel discussion between these four thought leaders.
Vice Provost for Global Initiatives and Chair of the Dept of Medical Ethics and Health Policy at UPenn.
Chancellor, Arthur and Toni Rembe Rock Distinguished Professor
Dean SOM, Vice Chancellor, Medical Affairs, UCSF
President and CEO UCSF Health
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5